Related references
Note: Only part of the references are listed.Phase 2 Trial of Bortezomib in Combination With Rituximab Plus Hyperfractionated Cyclophosphamide, Vincristine, Doxorubicin, and Dexamethasone Alternating With Bortezomib, Rituximab, Methotrexate, and Cytarabine for Untreated Mantle Cell Lymphoma
Jorge E. Romaguera et al.
CANCER (2018)
Anti-cancer Effects of HNHA and Lenvatinib by the Suppression of EMT-Mediated Drug Resistance in Cancer Stem Cells
Yong Sang Lee et al.
NEOPLASIA (2018)
Synergistic Activity of N-hydroxy-7(2-naphthylthio) Heptanomide and Sorafenib Against Cancer Stem Cells, Anaplastic Thyroid Cancer
Ki Cheong Park et al.
NEOPLASIA (2017)
miR-200c enhances sensitivity of drug-resistant non-small cell lung cancer to gefitinib by suppression of PI3K/Akt signaling pathway and inhibites cell migration via targeting ZEB1
Guohua Zhou et al.
BIOMEDICINE & PHARMACOTHERAPY (2017)
New knowledge of the mechanisms of sorafenib resistance in liver cancer
Yan-jing Zhu et al.
ACTA PHARMACOLOGICA SINICA (2017)
Selumetinib Inhibits Melanoma Metastasis to Mouse Liver via Suppression of EMT-targeted Genes
Seung-Hee Ryu et al.
ANTICANCER RESEARCH (2017)
Drug resistance originating from a TGF-β/FGF-2-driven epithelial-to-mesenchymal transition and its reversion in human lung adenocarcinoma cell lines harboring an EGFR mutation
Ryota Kurimoto et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2016)
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer
Bryan R. Haugen et al.
THYROID (2016)
Lenvatinib and other tyrosine kinase inhibitors for the treatment of radioiodine refractory, advanced, and progressive thyroid cancer
Loredana Lorusso et al.
ONCOTARGETS AND THERAPY (2016)
Epithelial-mesenchymal transition confers resistance to selective FGFR inhibitors in SNU-16 gastric cancer cells
Paulina Grygielewicz et al.
GASTRIC CANCER (2016)
Randomized phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations: NEJ005/TCOG0902
S. Sugawara et al.
ANNALS OF ONCOLOGY (2015)
ZEB1: At the crossroads of epithelial-mesenchymal transition, metastasis and therapy resistance
Peijing Zhang et al.
CELL CYCLE (2015)
ZEB1-associated drug resistance in cancer cells is reversed by the class I HDAC inhibitor mocetinostat
Simone Meidhof et al.
EMBO MOLECULAR MEDICINE (2015)
SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer
Christian Eichelberg et al.
EUROPEAN UROLOGY (2015)
Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer
Martin Schlumberger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Sorafenib, a multikinase inhibitor, induces formation of stress granules in hepatocarcinoma cells
Pauline Adjibade et al.
ONCOTARGET (2015)
Factors Affecting Outcomes of Alternating Chemoradiotherapy for Nasopharyngeal Cancer
Takayoshi Ueno et al.
ANNALS OF OTOLOGY RHINOLOGY AND LARYNGOLOGY (2014)
New therapeutic options for advanced forms of thyroid cancer
Victor Bernet et al.
EXPERT OPINION ON EMERGING DRUGS (2014)
Stemness in Human Thyroid Cancers and Derived Cell Lines: The Role of Asymmetrically Dividing Cancer Stem Cells Resistant to Chemotherapy
Risheng Ma et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial
Marcia S. Brose et al.
LANCET (2014)
Antitumor Activity of Lenvatinib (E7080): An Angiogenesis Inhibitor That Targets Multiple Receptor Tyrosine Kinases in Preclinical Human Thyroid Cancer Models
Osamu Tohyama et al.
JOURNAL OF THYROID RESEARCH (2014)
The Role of Epithelial Mesenchymal Transition Markers in Thyroid Carcinoma Progression
Celina Montemayor-Garcia et al.
ENDOCRINE PATHOLOGY (2013)
Epithelial-mesenchymal transition triggers cancer stem cell generation in human thyroid cancer cells
Ling Lan et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2013)
Approach to the Patient with Anaplastic Thyroid Carcinoma
Robert C. Smallridge
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
E7080, a multi-targeted tyrosine kinase inhibitor suppresses tumor cell migration and invasion
Hilary Glen et al.
BMC CANCER (2011)
Genetic Alterations in Poorly Differentiated and Undifferentiated Thyroid Carcinomas
Paula Soares et al.
CURRENT GENOMICS (2011)
Sequence Therapy in Patients with Metastatic Renal Cell Carcinoma: Comparison of Common Targeted Treatment Options Following Failure of Receptor Tyrosine Kinase Inhibitors
Jonas Busch et al.
EUROPEAN UROLOGY (2011)
Thyroid cancer is the most common cancer associated with acromegaly
Bennur Esen Gullu et al.
PITUITARY (2010)
The epithelial-mesenchymal transition generates cells with properties of stem cells
Sendurai A. Mani et al.
CELL (2008)
Thyroid carcinoma: molecular pathways and therapeutic targets
Yuri E. Nikiforov
MODERN PATHOLOGY (2008)
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
SM Wilhelm et al.
CANCER RESEARCH (2004)
Share Paper
